Table 1 Characteristics of included trials by anticancer drug type
ICPi (n = 3) | Other anticancer drug (n = 10) | |
|---|---|---|
Included drugs (n) | Ipilimumab, Pembrolizumab, Nivolumab | Abiraterone acetate, Brentuximab vedotin, Bosutinib, Ziv-aflibercept, Dabrafenib, Afatinib, Belinostat, Ramucirumab, Blinatumomab, Olaparib |
Drug approval characteristics, n (%) | Priority review 0, orphan drug 3 (100%), breakthrough therapy 2 (67%), accelerated approval 2 (67%) | Priority review 4 (40%), orphan drug 7 (70%), breakthrough therapy 1 (10%), accelerated approval 4 (40%) |
ICPi trials (n = 19) | Other anticancer drug trials (n = 101) | |
Study phase, n (%) | ||
Phase 1 | 5 (26) | 42 (42) |
Phase 2 | 9 (47) | 48 (48) |
Phase 3 | 5 (26) | 11 (11) |
Efficacy study, n (%) | 11 (58) | 18 (18) |
Randomized study, n (%) | 12 (63) | 28 (28) |
Double-blinded study, n (%) | 7 (37) | 13 (13) |
Multi-country study, n (%) | 12 (63) | 52 (51) |
Author affiliation with industry, n (%) | 18 (95) | 82 (81) |
Sample size, median (IQR) | 284 (127–676) | 58 (37–121) |
Statistically significant outcomeª, n (%) | 8 (42) | 10 (10) |
Reporting of adverse events, n (%) | 19 (100) | 91 (90) |
Selective outcome reporting, n (%) | 6 (32) | 21 (21) |